- Home
- QH vs PMCB Comparison
QH vs PMCB Comparison
Compare QH & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QH
- PMCB
- Stock Information
- Founded
- QH 2012
- PMCB 1996
- Country
- QH China
- PMCB United States
- Employees
- QH N/A
- PMCB N/A
- Industry
- QH Business Services
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QH Consumer Discretionary
- PMCB Health Care
- Exchange
- QH Nasdaq
- PMCB Nasdaq
- Market Cap
- QH 6.6M
- PMCB 6.6M
- IPO Year
- QH 2020
- PMCB N/A
- Fundamental
- Price
- QH $1.19
- PMCB $0.87
- Analyst Decision
- QH
- PMCB
- Analyst Count
- QH 0
- PMCB 0
- Target Price
- QH N/A
- PMCB N/A
- AVG Volume (30 Days)
- QH 5.2M
- PMCB 41.1K
- Earning Date
- QH 09-26-2025
- PMCB 12-12-2025
- Dividend Yield
- QH N/A
- PMCB N/A
- EPS Growth
- QH N/A
- PMCB N/A
- EPS
- QH 0.33
- PMCB 0.01
- Revenue
- QH $357,118,848.00
- PMCB N/A
- Revenue This Year
- QH N/A
- PMCB N/A
- Revenue Next Year
- QH N/A
- PMCB N/A
- P/E Ratio
- QH $2.54
- PMCB $139.50
- Revenue Growth
- QH N/A
- PMCB N/A
- 52 Week Low
- QH $0.74
- PMCB $0.79
- 52 Week High
- QH $169.07
- PMCB $1.94
- Technical
- Relative Strength Index (RSI)
- QH 35.40
- PMCB 35.21
- Support Level
- QH $0.74
- PMCB $0.79
- Resistance Level
- QH $1.20
- PMCB $0.93
- Average True Range (ATR)
- QH 0.98
- PMCB 0.05
- MACD
- QH -0.27
- PMCB -0.01
- Stochastic Oscillator
- QH 6.63
- PMCB 25.59
About QH Quhuo Limited American Depository Shares
Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.